A New Era for Ribavirin Aerosols to Treat Respiratory Syncitial Virus Infections in Immunocompromised Patients?

References

1. 1.↵
   1. Portnoy J,
   2. Nadel G,
   3. Amado M,
   4. Willsie-Ediger S

   . Continuous nebulization for status asthmaticus. Ann Allergy 1992;69(1):71–79.

   OpenUrlPubMedWeb of Science
2. 2.↵
   1. Newth CJ,
   2. Clark AR

   . In vitro performance of the small particle aerosol generator (SPAG-2). Pediatr Pulmonol 1989;7(3):183–188.

   OpenUrlPubMed
3. 3.↵
   1. Shah DP,
   2. Ghantoji SS,
   3. Shah JN,
   4. El Taoum KK,
   5. Jiang Y,
   6. Popat U,
   7. et al

   . Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 2013;68(8):1872–1880.

   OpenUrlAbstract/FREE Full Text
4. 4.
   1. Chemaly RF,
   2. Shah DP,
   3. Boeckh MJ

   . Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis 2014;59(Suppl 5):S344–S351.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Seo S,
   2. Campbell AP,
   3. Xie H,
   4. Chien JW,
   5. Leisenring WM,
   6. Englund JA,
   7. Boeckh M

   . Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant 2013;19(4):589–596.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Chemaly RF,
   2. Torres HA,
   3. Munsell MF,
   4. Shah DP,
   5. Rathod DB,
   6. Bodey GP,
   7. et al

   . An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis 2012;206(9):1367–1371.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Fätkenheuer G,
   2. Gillor D,
   3. Platten M,
   4. Kochanek M,
   5. Salzberger B

   . Aerosolized ribavirin for patients with cancer and respiratory syncytial virus infection. J Infect Dis 2013;207(10):1621.

   OpenUrlFREE Full Text
8. 8.↵
   1. Walsh BK,
   2. Betit P,
   3. Fink JB,
   4. Pereira LM,
   5. Arnold J

   . Characterization of ribavirin aerosols with small-particle aerosol generator and vibrating mesh micropump aerosol technologies. Respir Care 2016;61(5):577–585.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Martin AR,
   2. Finlay WH

   . Nebulizers for drug delivery to the lungs. Expert Opin Drug Deliv 2015;12(6):889–900.

   OpenUrlPubMed
10. 10.↵
    1. Ehrmann S,
    2. Roche-Campo F,
    3. Bodet-Contentin L,
    4. Razazi K,
    5. Dugernier J,
    6. Trenado-Alvarez J,
    7. et al

    . Aerosol therapy in intensive and intermediate care units: prospective observation of 2808 critically ill patients. Intensive Care Med. 2016;42(2):192–201

    OpenUrlPubMed
11. 11.↵
    1. Boukhettala N,
    2. Porée T,
    3. Diot P,
    4. Vecellio L

    . In vitro performance of spacers for aerosol delivery during adult mechanical ventilation. J Aerosol Med Pulm Drug Deliv 2015;28(2):130–136.

    OpenUrlPubMed
12. 12.↵
    1. Iacono AT,
    2. Johnson BA,
    3. Grgurich WF,
    4. Youssef JG,
    5. Corcoran TE,
    6. Seiler DA,
    7. et al

    . A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med 2006;354(2):141–150.

    OpenUrlCrossRefPubMedWeb of Science